Amivantamab Clinical Trials
14 recruitingDrug
Phase 29Phase 15Phase 33
Showing 1–14 of 14 trials
Recruiting
Phase 3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled160 locationsNCT07276399
Recruiting
Phase 1Phase 2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC287 enrolled55 locationsNCT06385080
Recruiting
Phase 1Phase 2
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC60 enrolled15 locationsNCT07227025
Recruiting
Phase 1Phase 2
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595
Recruiting
Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Phase 2
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Janssen Research & Development, LLC480 enrolled196 locationsNCT06667076
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled234 locationsNCT06750094
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled234 locationsNCT06662786
Recruiting
Phase 2
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest197 enrolled1 locationNCT05845450
Recruiting
Phase 2
Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
Metastatic NSCLC - Non-Small Cell Lung Cancer
Fondazione Ricerca Traslazionale33 enrolled1 locationNCT07392658
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Solid Tumor, Adult
Kumquat Biosciences Inc.100 enrolled35 locationsNCT06507306
Recruiting
Phase 2
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network88 enrolled213 locationsNCT06116682
Recruiting
Phase 1
5G-EMERALD: Amivantamab in Malignant Brain Tumours
Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom12 enrolled2 locationsNCT06632236
Recruiting
Phase 2
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Advanced Solid Tumor
Vall d'Hebron Institute of Oncology1,000 enrolled8 locationsNCT03767075